IFNAR2
Alternative Names: Type I interferon receptorLatest Information Update: 24 Sep 2021
At a glance
- Originator Merck Serono; Weizmann Institute of Science; Yeda
- Developer Merck Serono; Yeda
- Class
- Mechanism of Action Interferon alpha inhibitors; Interferon beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders; Multiple sclerosis
Most Recent Events
- 29 Mar 2004 Discontinued - Phase-I for Autoimmune disorders in Israel (unspecified route)
- 29 Mar 2004 Discontinued - Phase-II for Multiple sclerosis in Switzerland (unspecified route)
- 29 Mar 2004 Discontinued - Preclinical for Autoimmune disorders in Switzerland (unspecified route)